Search
for
Did you mean Janus Kinase Inhibitors?
Sort by
Research 30 of 1000+
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Janus Kinase Inhibitors in Dermatology: Part 1 — General Considerations and Applications in Vitiligo and Alopecia Areata
- The Janus kinase 1 inhibitor abrocitinib for the treatment of oral lichen planus
- 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
- 1332 Janus kinase inhibitor increases hair growth by increasing beta-catenin activity in outer root sheath cells
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
- Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- Inhibidores de JAK: usos en dermatología. Parte 1: generalidades, aplicaciones en vitíligo y en alopecia areata
- Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata
- Iron Chelators in the Management of Autoimmune-Induced Alopecia: A Focus on Hypoxia-Inducible Factor 1 Modulation and Hair Restoration
- Efficacy of Janus kinase inhibitors in adult patients with alopecia areata
- The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- BH21 Efficacy and safety of oral Janus kinase inhibitors in the treatment of alopecia areata: a systematic review and meta-analysis
- Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data
- 44182 Treatment with Oral Janus Kinase Inhibitors in Adults Patients with Alopecia Areata: A Systematic Review and Meta-Analysis
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- The Use of Janus Kinase Inhibitors for Primary Neutrophilic Cicatricial Alopecias
- Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
- Public Interest in Janus Kinase (JAK) IInhibitors for Alopecia Areata: A Google Trend Analysis
- Comparative efficacy of Janus kinase inhibitors in severe alopecia areata: a network meta-analysis based on randomized controlled trials
- Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T‐Cell Lymphoma: A Real‐World Single‐Center Experience
- Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
- Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: A case report
- Upadacitinib for management of recalcitrant alopecia areata: A retrospective case series
- Upadacitinib for management of alopecia areata and rheumatoid arthritis: Letter to the editor
- Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib